Price Chart

Executive Summary

Akzo Nobel N.V. issued a definitive shareholder circular convening an extraordinary general meeting (EGM) on August 5, 2026, to approve the all-share merger of equals with Axalta Coating Systems Ltd. The circular provides the complete technical framework for the merger vote, including the fixed exchange ratio of 0.6539 AkzoNobel shares per Axalta share, a special pre-completion dividend of EUR 2.5 billion to AkzoNobel shareholders, and pro forma financials showing combined revenue of ~$17 billion, adjusted EBITDA of $3.3 billion, and ~$600 million in pre-tax run-rate synergies. This filing advances the deal toward the shareholder vote and includes confidence-boosting details like fairness opinions from Morgan Stanley and Lazard, but no new substantive changes to deal terms.

Key Financial Metrics

Key Facts

• Axa shareholders to receive 0.6539 AkzoNobel ordinary shares per Axalta common share (fixed exchange ratio, no collar).
• AkzoNobel shareholders to hold ~55% of MergeCo on a pro forma basis; Axalta shareholders ~45%.
• AkzoNobel declares a special pre-completion cash dividend of EUR 2.5 billion (minus 2026 interim dividends already paid).
• Pro forma MergeCo expected to generate ~$17 billion revenue, $3.3 billion adjusted EBITDA, and $1.5 billion adjusted free cash flow.
• Expected pre-tax run-rate synergies of ~$600 million, with 90% expected within three years of closing.
• Both AkzoNobel and Axalta shareholder meetings scheduled for August 5, 2026; closing expected late 2026 to early 2027.
• AkzoNobel receives fairness opinions from Morgan Stanley and Lazard that the Exchange Ratio is fair from a financial point of view to AkzoNobel.
• AkzoNobel would pay a EUR 150 million termination fee if the board changes its recommendation; Axalta can terminate for a superior proposal.
• Merger sub 1 (Bermuda) will merge into Axalta; post-closing, Axalta merges into Merger Sub 2, a direct wholly-owned subsidiary of AkzoNobel.
• MergeCo will have dual headquarters in Amsterdam and Philadelphia; initially listed on NYSE and Euronext Amsterdam, with Euronext delisting expected after ~12 months.

Financial Impact

Pro forma MergeCo expected to generate approximately $17 billion in revenue, $3.3 billion in adjusted EBITDA, and $1.5 billion in adjusted free cash flow; pre-tax run-rate synergies estimated at $600 million, with 90% achieved within three years. AkzoNobel to distribute EUR 2.5 billion special dividend prior to completion.

Risk Factors

• Regulatory approvals (merger control in EU, UK, US; FDI filings; Foreign Subsidies Regulation) may impose conditions or fail to materialize
• Shareholders of either company may vote against the merger
• Integration of two large cross-border businesses carries execution risk; expected synergies may fail to materialize
• Fixed exchange ratio exposes AkzoNobel shareholders to relative stock price movements adverse to AkzoNobel
• AkzoNobel may be required to pay EUR 150 million termination fee if board changes recommendation
• Euronext Amsterdam de-listing ~12 months post-closing adds risk of reduced European shareholder base

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status

Related Tickers